5A87 image
Deposition Date 2015-07-13
Release Date 2015-12-23
Last Version Date 2024-01-10
Entry Detail
PDB ID:
5A87
Keywords:
Title:
Crystal structure of the metallo-beta-lactamase VIM-5
Biological Source:
Source Organism:
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.50 Å
R-Value Free:
0.19
R-Value Work:
0.15
R-Value Observed:
0.15
Space Group:
P 1 21 1
Macromolecular Entities
Structures with similar UniProt ID
Protein Blast
Polymer Type:polypeptide(L)
Molecule:METALLO-BETA-LACTAMASE VIM-5
Chain IDs:A, B
Chain Length:248
Number of Molecules:2
Biological Source:KLEBSIELLA PNEUMONIAE
Primary Citation
Comparison of Verona Integron-Borne Metallo-beta-Lactamase (VIM) Variants Reveals Differences in Stability and Inhibition Profiles.
Antimicrob. Agents Chemother. 60 1377 1384 (2015)
PMID: 26666919 DOI: 10.1128/AAC.01768-15

Abstact

Metallo-β-lactamases (MBLs) are of increasing clinical significance; the development of clinically useful MBL inhibitors is challenged by the rapid evolution of variant MBLs. The Verona integron-borne metallo-β-lactamase (VIM) enzymes are among the most widely distributed MBLs, with >40 VIM variants having been reported. We report on the crystallographic analysis of VIM-5 and comparison of biochemical and biophysical properties of VIM-1, VIM-2, VIM-4, VIM-5, and VIM-38. Recombinant VIM variants were produced and purified, and their secondary structure and thermal stabilities were investigated by circular dichroism analyses. Steady-state kinetic analyses with a representative panel of β-lactam substrates were carried out to compare the catalytic efficiencies of the VIM variants. Furthermore, a set of metalloenzyme inhibitors were screened to compare their effects on the different VIM variants. The results reveal only small variations in the kinetic parameters of the VIM variants but substantial differences in their thermal stabilities and inhibition profiles. Overall, these results support the proposal that protein stability may be a factor in MBL evolution and highlight the importance of screening MBL variants during inhibitor development programs.

Legend

Protein

Chemical

Disease

Primary Citation of related structures